Treatment of Helicobacter pylori infection: Current and future insights

作     者：Maliheh Safavi Reyhaneh Sabourian Alireza Foroumadi 

作者机构：Department of BiotechnologyIranian Research Organization for Science and Technology Department of Drug and Food Control Faculty of PharmacyTehran University of Medical Sciences Pharmaceutical Sciences Research Center Tehran University of Medical Sciences 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2016年第4卷第1期

页      面：5-19页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Helicobacter pylori Therapeutic regimens Probiotics Photodynamic Phytomedicine 

摘      要：Helicobacter pylori(***) is an important major cause of peptic ulcer disease and gastric malignancies such as mucosa-associated lymphoid tissue lymphoma and gastric adenocarcinoma *** treatment still remains a challenge,since many determinants for successful therapy are involved such as individual primary or secondary antibiotics resistance,mucosal drug concentration,patient compliance,side-effect profile and *** no new drug has been developed,current therapy still relies on different mixture of known antibiotics and anti-secretory agents.A standard triple therapy consisting of two antibiotics and a proton-pump inhibitor proposed as the first-line *** quadruple treatment,sequential treatment or a non-bismuth quadruple treatment(concomitant) are also an alternative *** containing triple treatment are recommended as rescue treatment for infection of *** after defeat of first-line *** rapid acquisition of antibiotic resistance reduces the effectiveness of any regimens involving these ***,adding probiotic to the medications,developing *** photodynamic or phytomedicine therapy,and achieving a successful *** vaccine may have the promising to present synergistic or additive consequence against ***,because each of them exert different effects.